Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
OTC Drugs

HHS Nominee Sebelius Aims To Restore Science-based Approach At FDA

This article was originally published in The Tan Sheet

  • News
  • The Tan Sheet

Executive Summary

Kathleen Sebelius, President Obama's nominee for Department of Health and Human Services secretary, said she intends to restore trust in FDA by ensuring the agency's decisions are science-based

You may also be interested in...



Sebelius Plans To Leave Plan B Decision To Science

Doctors and scientists, not politicians, must evaluate the safety of the emergency contraceptive Plan B, says Kathleen Sebelius, the Department of Health and Human Services secretary nominee

Sebelius Plans To Leave Plan B Decision To Science

Doctors and scientists, not politicians, must evaluate the safety of the emergency contraceptive Plan B, says Kathleen Sebelius, the Department of Health and Human Services secretary nominee

Sebelius Plans To Leave Plan B Decision To Science

Doctors and scientists, not politicians, must evaluate the safety of the emergency contraceptive Plan B, says Kathleen Sebelius, the Department of Health and Human Services secretary nominee

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet

Topics

Tags:
OTC Drugs
Latest Headlines

Products Targeting Alzheimer's, Duchenne & COVID-19 Among New EU Filings

Gene Therapy HTA: How Do The European, Australian And Canadian Systems Shape Up?

Coronavirus Notebook: UN Pandemic Declaration Disappoints, Focus Turns To Draft WHO Treaty

Finding The Sweet Spot For Real-World Evidence: Aetion Stresses Early Feasibility Assessment

See All
UsernamePublicRestriction

Register

PS102777

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By